Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related …


The success of adipose stem cells

Cell therapy specialist TiGenix has announced that their product for the treatment of complex perianal fistulas, Cx601, has met the primary endpoi…


IPO Bone Therapeutics yields 32.2 million euro

Bone Therapeutics – a Walloon cell therapy company specialized in bone fracture repair and prevention – shifts up a gear and raises 32.2 million e…

POPULAR TAGS

TiGenix inks massive deal with Takeda

Written by LVS on in the category news with the tags , , .


Today cell therapy specialist TiGenix has disclosed a new deal with the Japanese pharmaceutical giant Takeda. The agreement allows Takeda the rights to license, develop and sell TiGenix’ Cx601 globally, except for the US, where a phase III trial is still underway. Cx601 is a cell therapy for the treatment of complex perianal fistulas in Crohn’s disease patients, based on the patient’s own adipose stem cells. Cx601 passed its first phase III clinical trial back in September, and is now awaiting marketing authorization in Europe.

Takeda will pay 25 million upfront and TiGenix is eligible for additional milestone payments to up to 355 million plus royalties on Cx601 sales.

“TiGenix is pleased to partner with Takeda, a global pharmaceutical company with a strong track record and strong leadership position in gastroenterology. This agreement reduces the investment risks associated with building a pan-European marketing and selling infrastructure, and helps get this much-needed treatment option to patients and gives to Cx601 the best partner with the needed capabilities and resources to secure its commercial success” said Eduardo Bravo, CEO at TiGenix. "This agreement further provides TiGenix with the financial strength to move forward with the clinical development of Cx601 in the U.S., which represents approximately 50 percent of the world’s Crohn’s market."

Read more on TiGenix and its adipose stem cell therapy Cx601 here

Read more about: , , .

RELATED ARTICLES
Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related …


The success of adipose stem cells

Cell therapy specialist TiGenix has announced that their product for the treatment of complex perianal fistulas, Cx601, has met the primary endpoi…


IPO Bone Therapeutics yields 32.2 million euro

Bone Therapeutics – a Walloon cell therapy company specialized in bone fracture repair and prevention – shifts up a gear and raises 32.2 million e…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Janssen V-Bio Ventures UGent GSK XpandInnovation Flanders.bio Turnstone KU Leuven Biowin Itera Life Science

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.